Boothwyn Pharmacy recalls 648 vials of semaglutide 2.5 mg/mL injection nationwide after detecting subpotent potency. The recall involves products distributed across the U.S. and is classified as Class II with a high hazard level. Stop using the product and contact Boothwyn Pharmacy or a healthcare provider for guidance.
Subpotent Drug
Consumers and healthcare providers should stop using this product immediately. Contact Boothwyn Pharmacy LLC or your healthcare provider for guidance. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Semaglutide injections are used to treat type 2 diabetes and obesity under medical supervision. They are typically prescribed by healthcare providers.
Subpotent potency may reduce drug effectiveness and clinical outcomes, requiring medical adjustment.
This recall is not described as part of a broader industry pattern in the provided data.
Consumers and patients may need alternative therapies or dosage adjustments as advised by clinicians.
FDA enforcement listing linked in recall notice; Boothwyn Pharmacy customer service
Refund or replacement timelines will be set by Boothwyn Pharmacy after recall validation
Keep recall notice, purchase documentation, model numbers, communication with pharmacy, and any adverse events.
Product: Semaglutide injection. Strength: 2.5 mg/mL. Volume: 4 mL per vial. Quantity: 648 vials. Brand: Boothwyn Pharmacy. Distribution: U.S. nationwide. Recall date: 2025-07-09. Status: Active.
No injuries or incidents are described in the provided data. The status is active with no incident counts specified.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Boothwyn Pharmacy LLC issued a nationwide recall of 186 vials of Semaglutide 2.5 mg/mL injection, 0.8 mL, on July 9, 2025. The FDA enforcement report classifies the recall as Class II with a high hazard level. Consumers and healthcare providers should stop using the product immediately and follow guidance from Boothwyn Pharmacy or a healthcare provider.
Boothwyn Pharmacy recalls 642 vials of semaglutide 2.5 mg/mL injection sold nationwide in the U.S. The recall cites subpotent drug with Class II designation. Consumers and healthcare providers should stop using the product immediately and contact Boothwyn Pharmacy for guidance.
Boothwyn Pharmacy recalls 8 vials of Fluorescein 2% Ophth 3 mL nationwide after a subpotent drug finding. The recall was issued July 9, 2025 and remains active.